Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs Novavax Inc — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.5, while Novavax Inc trades at $7.95 (market cap $1.30B). The key difference: State Street SPDR Bloomberg 1-3 Month T-Bill ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| BIL | NVAX | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $91.77 | $11.19 |
52-Week Low | $91.27 | $6.22 |
Market Cap | — | $1.30B |
Enterprise Value | — | $879.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIL trades at $91.48 with minimal daily movement (+0.03%), showing stability amid market volatility. The ETF maintains consistent dividend distributions of $0.27 per share quarterly, with recent institutional buying activity indicating professional confidence. Technical indicators show bearish momentum with moving averages signaling caution, though oscillators suggest potential stabilization near current levels.
As a short-term Treasury ETF, BIL offers capital preservation and steady income through Treasury bill exposure. Key risks include interest rate sensitivity and inflation pressures affecting Treasury yields. The fund's defensive positioning appeals to risk-averse investors seeking liquidity and minimal credit risk in uncertain markets.
Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.
Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
